

UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT  
PURSUANT TO SECTION 13 OR 15(d)  
OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): January 8, 2026

**60 DEGREES PHARMACEUTICALS, INC.**  
(Exact name of registrant as specified in its charter)

**Delaware**

(State or other jurisdiction  
of Incorporation)

**001-41719**

(Commission File Number)

**45-2406880**

(IRS Employer  
Identification Number)

**1025 Connecticut Avenue NW Suite 1000,  
Washington, D.C.**

(Address of registrant's principal executive office)

**20036**

(Zip code)

**(202) 327-5422**

(Registrant's telephone number, including area code)

**Not Applicable**

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

<b>Title of each class</b>	<b>Trading symbol(s)</b>	<b>Name of each exchange on which registered</b>
Common Stock, par value \$0.0001 per share	SXTP	The Nasdaq Stock Market LLC
Warrants, each warrant to purchase one share of Common Stock	SXTPW	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

**Item 7.01 Regulation FD Disclosure**

On January 8, 2026, 60 Degrees Pharmaceuticals, Inc. (the “Company”) made available an investor presentation in connection with a webinar presentation hosted by RedChip Companies, Inc. The presentation includes, among other things, updated information regarding the Company’s clinical development timelines and regulatory strategy.

A copy of the investor presentation is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished pursuant to Regulation FD and shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall it be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

The presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. The Company undertakes no obligation to update or revise any forward-looking statements, except as required by law.

**Item 9.01 Financial Statements and Exhibits**

<b>Exhibit Number</b>	<b>Description</b>
99.1	<a href="#">Investor Presentation, dated January 8, 2026</a>
104	Cover page Interactive Data File (embedded within the Inline XBRL document).

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

**60 DEGREES PHARMACEUTICALS, INC.**

Date: January 8, 2026

By: /s/ Geoffrey Dow

Name: Geoffrey Dow

Title: Chief Executive Officer and President

October 2025



1-8-26 Webinar

©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



## Disclaimer and Forward-looking Statements


**DISCLAIMER.** The information contained herein has been prepared to assist prospective investors in making their own evaluation of 60 Degrees Pharmaceuticals, Inc. (the "Company") and does not purport to be all-inclusive or to contain all of the information a prospective or existing investor may desire. In all cases, interested parties will be expected to have conducted their own due diligence investigation regarding these and all other matters pertinent to investment in the Company. The Company makes no representation or warrant as to the accuracy or completeness of this information and shall not have any liability for any representations (expressed or implied) regarding information contained in, or for any omissions from, this information or any other written or oral communications transmitted to the recipient in the course of its evaluation of the Company. This presentation and contents herein are the exclusive property of the Company and may not be copied without the express prior written consent of the Company.

**FORWARD LOOKING STATEMENTS.** This communication includes forward-looking statements based on the Company's current expectations and projections about future events. All statements contained in this communication other than statements of historical fact, including any statements regarding our future operations, are forward-looking statements. The words "believe", "may", "will", "estimate", "continue", "anticipate", "intend", "expect", "could", "would", "project", "plan", "potentially", "likely" and similar expressions are intended to identify forward-looking statements as defined in the Private securities Litigation Reform Act of 1995.

The forward-looking statements contained in this communication are based on knowledge of the environment in which the Company currently operates and are subject to changed based on various important factors that may affect the Company's operations, growth strategies, financial results and cash flows, and as well as other factors beyond the Company's control as of the date of this presentation.

Important factors that could cause our actual results and financial conditions to differ materially from those indicated in the forward-looking statements include, among others, the following: there is substantial doubt as to our ability to continue on a going-concern basis; we might not be eligible for Australian government research and development tax rebates; if we are not able to successfully develop, obtain FDA approval for, and otherwise provide for the commercialization of non-malaria prevention indications for Tafenoquine (ARAKODA or other regimen) or Celgosivir/Australian Chestnut extracts in a timely manner, we may not be able to expand our business operations; we cannot guarantee our ability to conduct successful clinical trials; and we have no manufacturing capacity which poses the risk of lengthy and costly delays of bringing our products to market. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including our Annual Report on Form 10-K and our subsequent Quarterly Reports on Form 10-Q. Investors and security holders are urged to read these documents free of charge on the SEC's website at [www.sec.gov](http://www.sec.gov). As a result of these matters, changes in fact, assumptions not being realized or other circumstances, the Company's actual results may differ materially from the expected results discussed in the forward-looking statements contained in this presentation.

In light of these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements, which speak only as of the date of this presentation. Although we believe our expectations are based on reasonable assumptions, we can give no assurance that our expectations will materialize. Unless required by law, we undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.




Market Cap:  
\$2.1 million



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

# Use of ARAKODA for Chronic Babesiosis Is Increasing Sales



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



## Gross Margins Look Good, So Our Focus is on Increasing Sales

Net Revenue and Gross Margin in thousands



	Q3 23	Q4 23	Q1 24	Q2 24	Q3 24	Q4 24	Q1 25	Q2 25	Q3 25
US Pharmacy Deliveries (16 ct box equivalents)	550	566	1,022	1,301	1,319	1,477	1,579	1,082	1,505
Product Revenues, Net (Loss)	51	126	106	125	135	242	164	101	438
Gross (Loss) Profit (\$)	(20)	(21)	40	35	24	124	90	51	(100)
Gross (Loss) Profit (%)	(39%)	(16%)	38%	28%	17%	51%	55%	50%	(23%)

Notes:

1. Q2 2025 Pharmacy Deliveries down due to temporary stock out.
2. Q3 2025 Net Loss due to anticipated expiring inventory write-off of last of short dated product.




# Future Sales of Arakoda Could Increase by Orders of Magnitude\*



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

***\*Assuming company market research is accurate and FDA approval of Arakoda is achieved***

# Future Arakoda Sales for Chronic Babesiosis Could be Higher Than Malaria\*



■ Malaria Prevention ■ Chronic Babesiosis ■ Other Babesiosis



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

*\*Based on internal market research that assumes FDA approval Arakoda for treatment of babesiosis*

---



# Fox News' John Roberts Shares Health Update After Battling 'Awful' Malaria

Kristie Lau-Adams


Tue, September 2, 2025 at 11:12 PM EDT

Roberts wrote, "Malaria is an awful disease that needs to be attacked full-force when a diagnosis is made. In my time here, I've gone from being so sick that any dog would take pity on me to being ready to fire up the grill on Labor Day (well, maybe ready to watch the grill being fired up)."



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

# Malaria in Travelers is Increasing Because They Don't Take Their Meds



No vaccines

95% of cases in people who don't take their meds


References: 1. Mace KE, et al. *MMWR Surveill Summ*. 2022;71(8):1-35. 2. Centers for Disease Control and Prevention. 2023. <https://emergency.cdc.gov/han/2023/han00496.asp#:~:text=This%20follows%20the%20identification%20of,in%20Texas%20in%20June%202023.>

©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.




# Selecting The Correct Antimalarial Prophylaxis is Complicated!

*P. vivax* (relapses post travel)




*P. falciparum* (deadly but does not relapse)



Very little *P. vivax* malaria in Africa




## ARAKODA Has a Lower Pill Burden\*



**Standard of care**  
**Atovaquone/proguanil/primaquine**  
**53 pills**

*\*For one month trip*



**ARAKODA**  
**16 pills**

©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



## Arakoda Market Research Revealed Some Challenges to Solve



**Brand recognition is low**



**HCPs and patients liked product profile**



**Generic alternatives have lower out of pocket costs**



**G6PD testing requirement a potential barrier for some travelers**



# Commercial Pilot for Malaria Indication Addresses Barriers to Use



## Increase Awareness and Differentiate ARAKODA

Differentiate ARAKODA from the generic competition with a clear and compelling value story through different channels



## Drive ARAKODA Trial & Usage


Additional Inside Sales Representatives - Encourage HCPS to prescribe ARAKODA for appropriate patients based on product attributes



## Facilitate Access & Affordability

Manage high OOP through GoodRx point of sale discount

# Babesiosis is a Parasite Transmitted By Ticks and Blood Donation




Reference: 1. Centers for Disease Control. Babesiosis. 2017. [www.cdc.gov/dpdx/babesiosis/index.html](http://www.cdc.gov/dpdx/babesiosis/index.html)

©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



# Blood Donation Screening Decreases Babesia Transmission, Revealing Hidden Reservoir of Viable Parasites




**FIGURE 4** Cases of TTB investigated by the ARC, and the number of cases with identified positive donors since 2010. The two cases identified in 2020 were collected before blood screening implementation, and the involved donations were not screened for *Babesia*

**Observation:** Blood donors usually do not donate blood if they are feeling sick and would likely not know they had a *Babesia* infection



# Conventional Treatments Resolve Symptoms of Babesiosis, But Unclear if Parasite Reservoirs Are Eliminated

Diagnostic Method(s)	Target	Lower Limit of Analytical Sensitivity (parasites/mL)
Microscopy	Whole organisms	100,000
Real Time PCR (e.g. Mayo)	18s RNA probe (DNA)	1,540
Blood Bank Test (transcription amplified)	RNA	3



Observation: Treated patients are unlikely have cleared their infections at Week 12



Question: Does the residual parasite burden have clinical significance?

Reference: Krause et al NEJM 2000;343:1454-1458


©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



# Clinical Significance of Residual Parasite Burden: Main-Stream Perspective



## Clinical Significance of Persistent Infection in Individuals With Dysregulated Immune Systems Has Not Been Studied



## Chronic Babesiosis is a Problem: Prescribing Physician Perspective

Dr. Richard Horowitz:


“Chronic Babesiosis is seen in the vast majority of my chronically ill patients with Lyme disease. Present regimens with Mepron and Zithromax or clindamycin and quinine are insufficient in many cases to clear the infection. We need more studies on drugs like tafenoquine, for Chronic Babesiosis, as this persistent parasite is one of the reasons my patients do not get better”

Dr. Shannon Delaney:

“Every week I see kids and adults who have manifestations of Chronic Babesiosis, often presenting as severe neuropsychiatric symptoms”



# Tafenoquine Kills Babesia and Malaria Parasites the Same Way, at Similar Doses




Giemsa-stained blood smears of *B. rodhaini*-infected mice from vehicle alone, 24 hours post single-dose tafenoquine delivery, and after 2 hours of incubation with 100  $\mu$ M H<sub>2</sub>O<sub>2</sub> *in vitro*

Tafenoquine kills Babesia and Malaria parasites in the same way  
Similar doses clear both infections in animal models



# Tafenoquine Had an 80% Cure Rate in 5 Immunosuppressed Babesiosis Patients With Weekly Dosing Plus Standard of Care<sup>1</sup>

## Representative Case



1. Krause PJ, et al. Clin Infect Dis. doi:10.1093/cid/ciae238

## Research Strategy Focused on FDA Approval and Broadening Acceptance

Demonstrate clinical improvement over standard of care and no new safety signal

Prove that chronic babesiosis can be diagnostically confirmed

Apply for Commissioner's NPRV or regular sNDA route

Request broadest possible labeling for treatment of babesiosis

Earliest feasible submission date is Q4 2026



## Three Clinical Trials of Arakoda Will Confirm Efficacy Against Babesiosis and That Chronic Babesiosis Is Associated With Persistent Infection\*

Trial #	ARAKODA Dose	Combined With	Population	Type	Min/Max Sample Size	Number Enrolled	Initial Enrolment Complete^
NCT06207370	~ 5 weeks	AA#	Hospitalized	Randomized, placebo Controlled	N=24/66	19	Earliest 8/15/2026
NCT06478641	Up to one year	IDSA SOC##	Relapsing, high risk	Open label	N=3/15	3	Will be deemed met if all 3 cured
NCT06656351	3 months	Not required	Chronic	Open label	N=25/100	2	Earliest 5/31/2026

\*Atovaquone/azithromycin for 7-10 days

\*\*Infectious Disease Society of America recommended standard of care

^May keep enrolling beyond the minimum required if resources permit and depending on status of regulatory discussions

**\*Or not.**



©2025 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.



**60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study**

October 15, 2025 11:14 AM EDT



**60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State**

December 29, 2025 1:01 PM EST

- Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA<sup>®</sup> (**tafenoquine**) for treatment of chronic babesiosis
  - Data support theory among specialists that *Babesia* infection may prolong recovery times in patients with chronic fatigue
-

# NCT96656351 May Prove Chronic Babesiosis is Due to Persistent Infection\*



## A Phase II Open Label Study of Tafenoquine in Chronic Babesiosis Patients



### Patients (key inclusions)

Severe disabling fatigue with substantial functional impairment, present for at least six months  
At least one other symptom of babesiosis  
Laboratory evidence of exposure in the last 12 months



### Number of Participants:

Up to 100 patients until N=16 in the PP population completed  
*Per protocol population defined based on positive blood bank test*



Tafenoquine: 200 mg/day on Days 1,2,3 and 4, then 200 mg weekly through Day 89 (as ARAKODA).  
Conmeds: No concomitant medication exclusions except quinine or per ARAKODA prescribing PI



Primary Endpoint: Change from baseline through Day 90 in patient-reported MFI – GF Subscale  
Other Important Endpoints:

*Proportion with molecular evidence of Babesia infection at baseline (digital PCR, real time PCR, NAT)*  
Incidence of molecular cure through Day 90




Setting: Outpatient (in clinical visits at Mt Sinai)

**\*Or not.**

©2024 60 Degrees Pharmaceuticals, Inc. CONFIDENTIAL All rights reserved.

# Achieving Key Milestones Will Derisk Business Plan in 2026



## Other Anticipated Milestones

Market updates

Outcomes from research pilot studies

Trade & scientific conferences

New product development collaborations

